A new study looked at what methods were used to detect recurrences of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma to see if surveillance guidelines recommended by the National Comprehensive Cancer Center were effective.
Final results of the trial that led to FDA approval show that a new 9-valent HPV vaccine can reduce cases of HPV and cervical cancer.
Women in routine gynecologic care expressed willingness to extend screening intervals and use cytology alone or Pap-HPV cotesting if recommended by a physician.
A new human papillomavirus (HPV) vaccine that protects against nine types of HPV and would protect against about 90% of cervical cancers could be available in 2015.
In light of the recent FDA approval of HPV testing for women as a screening method for cervical cancer, we discuss changing guidelines with two experts.
The FDA has approved an HPV DNA test to be used as a primary screening method for cervical cancer in women 25 and older. The test can also give insight into future risk of cervical cancer.
Don’t let time constraints and large patient loads prevent you from providing a thorough well-woman visit. Are you covering all the bases?
An FDA panel has recommended that a DNA test that screens for HPV in women can replace the standard Pap smear as a first-line primary cervical cancer screening test.
The 400-meter timed walk can provide insights into an older person’s cardiorespiratory fitness; the resulting data from these walks are useful in predicting total mortality, cardiovascular disease, mobility limitation, and disability. But do leisure time activities and weight/body composition changes affect walk time? Dr Kelley K. Pettee Gabriel from the division of epidemiology, human genetics, and environmental sciences at the University of Texas Health Science Center, Austin, and colleagues believe a better understanding of this relationship will help clarify the best use of the 400-meter walk in middle-aged women.